Pipeline

1. Structure based design approach for developing RNA modulatory compounds

2. Pre-cancer and cancer stem cell organoid bioreactor platforms for inhibitor screening

 

3. Hematopoietic stem cell bioreactor platform for therapeutic index and stem cell expansion assays

IMG_0041.jpeg

Other ADAR1 inhibitory strategies are under development